Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD
Nora Drick, Jan Fuge, Benjamin Seeliger, Milan Speth, Jens Vogel-Claussen, Tobias Welte, Hendrik Suhling
Source: ERJ Open Res, 8 (4) 00207-2022; 10.1183/23120541.00207-2022
For technical reasons, this interactive material needs to open in a new window. Please allow pop-ups from ers-education.org. If the window did not open automatically, please click here.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Nora Drick, Jan Fuge, Benjamin Seeliger, Milan Speth, Jens Vogel-Claussen, Tobias Welte, Hendrik Suhling. Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD. ERJ Open Res, 8 (4) 00207-2022; 10.1183/23120541.00207-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|